[A26-45] Nivolumab (urothelial carcinoma, adjuvant) – Addendum to Project A25-154
Last updated 05.06.2026
Project no.:
A26-45
Commission:
Commission awarded on 29.04.2026 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with muscle invasive urothelial carcinoma with tumour cell PD-L1 expression ≥ 1% and a high risk of recurrence after undergoing radical resection, for whom cisplatin-containing therapy is not suitable or who have already received neoadjuvant treatment with cisplatin; adjuvant treatment
- Male patients: unchanged after addendum: hint of a minor added benefit
- Female patients: unchanged after addendum: added benefit not proven
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A26-45
| Project no. | Title | Status |
|---|---|---|
| A25-154 | Nivolumab (urothelial carcinoma, adjuvant) – Benefit assessment according to §35a Social Code Book V (expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
05-06-2026 A G-BA decision was published.
G-BA documents on this decision